Eli Lilly Exec Says Seeing Out of Pocket Payments for Obesity Drug in US

Published on June 10, 2024

A top Eli Lilly (LLY.N), opens new tab executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro.Patrik Jonsson, President of Lilly Diabetes and Obesity, speaking at a Goldman…

Read Full Article (External Site)